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β-Glucans are naturally occurring polysaccharides that are 
produced by bacteria, yeast, fungi, and many plants. Although 
their pharmacological activities, such as immunomodulatory, 
anti-infective and anti-cancer effects, have been well stud-
ied, it is still unclear how β-glucans exert their activities. 
However, recent studies on the β-glucan receptors shed 
some light on their mechanism of action. Since β-glucans 
have large molecular weights, they must bind surface re-
ceptors to activate immune cells. In this review, we summa-
rize the immunopharmacological activities and the potential 
receptors of β-glucans in immune cells.
[Immune Network 2011;11(4):191-195]
CHEMISTRY OF β-GLUCANS
β-Glucans  are  heterogeneous  polysaccharides  of  glucose 
p o l y m e r ,  c o n s i s t i n g  o f  a  b a c k b o n e  o f  β-(1-3)-linked  β
-D-glucopyranosyl  units  with  β-(1-6)-linked  side  chains  of 
varying distribution and length. The activity of β-glucan de-
pends on the molecular structure, size, branching frequency, 
structural  modification,  conformation,  and  solubility.  It  ap-
p e a r s  t h a t  t h e  m o s t  a c t i v e  f o r m s  o f  β-glucans  contain  β
-(1-3)(1-6) linkages (1). The structure of several biologically 
active β-glucans has been reported. β-Glucan from many 
mushrooms  has  a  β-(1-3)  backbone  with  shorter  β-(1-6) 
linked  branches,  while  β-glucan  from  Alcaligenes  faecalis 
contains only β-(1-3)-glucosidic linkages (2). Schizophyllan 
from  Schizophyllum  commune  and  scleroglucan  from 
Sclerotium  glucanicum  both  have  a  β-(1→3)  linked  back-
bone  with  one  β-(1→6)-glucose  substitution  every  three 
backbone residues (3). Lentinan from Lentinus edodes has a 
β-(1→3) linked backbone and two β-(1→6) side chains ev-
ery five residues (4). β-Glucan from oat and barley are linear 
with  β-(1-4)  linkage  with  shorter  stretches  of  β-(1-3) (3). 
    Biologically active β-glucans usually have a large molec-
ular weight. However, it is unclear whether β-glucans hav-
ing  intermediate  or  small  molecular  weight  have  biological 
activities, although some of them are active in vivo. Short β- 
glucans below 5,000-10,000 Da of molecular weight are gen-
erally inactive (5). The optimal branching frequency is sug-
gested as 0.2 (1 in 5 backbone residues) to 0.33. Although 
unbranched β-glucan curdlan showed proper biological ac-
tivity,  chemical addition of  β-(1-6)  glucose residues  to the 
curdlan backbone led to an increase in anti-tumor activity (6), 
as highly branched β-glucan has higher affinity for cognate 
receptors (7). Furthermore, soluble β-glucans appear to be 
stronger  immunostimulators  than  insoluble  ones.  When  in-
soluble  scleroglucan  is  modified  by  sulfation  or  carbox-
ymethylation,  the  anti-tumor  activity  increases  (8). 
    Further study is still required before we will fully under-
stand the structure-activity relationship in β-glucans. Orally 
administered  β-glucans  may  be  modified  to  smaller  oligo-
saccharides in vivo (3). Thus, the actual β-glucans binding 
to the immune cell surface receptors in vivo may in fact be 
these smaller ones. However, there is no information on this 
topic to date. If we can use standardize smaller β-glucans, 
the  biological  data  might  be  fruitful.
IMMUNOPHARMACOLOICAL ACTIVITY OF 
β-GLUCANS
β-Glucans,  generally  called  biological  response  modifiers, 
are  now  recognized  as  anti-tumor  and  anti-infective  drugs. 
The  most  popular  β-glucan  is  lentinan,  which  is  isolated Biological Activity of β-glucan
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from fruiting bodies of Lentinus edodes is the most popular 
β-glucan and is a well-known drug with anti-tumor and an-
ti-infective activities (9). β-Glucan has been shown to protect 
against infection by bacteria, viruses, and pathogenic micro-
organisms  (10).  β-Glucan  also  prevents  cancer  promotion 
and  progression  and  has  synergistic  anti-tumor  effects  with 
monoclonal  antibodies  and  cancer  chemotherapeutics  (11). 
β-Glucan promotes antibody-dependent cellular cytotoxicity 
through a biological pathway involved in carcinogenesis (12). 
However, lentinan might not directly affect cancer cells or in-
fectious microorganisms. There are no reports on the direct 
effect of lentinan on these cells. Instead, it is believed that 
lentinan shows these biological activities through activation of 
host  immune  systems. 
    The effects of β-glucans on immune cells are well establi-
shed. Traditionally, macrophages and dendritic cells are con-
sidered  the  main  target  cells  of  β-glucans,  although  neu-
trophils,  B  cells,  T  cells,  and  natural  killer  cells  are  also 
known to be activated by β-glucan. The immunomodulatory 
activities of β-glucans are usually studied with regard to the 
activation of macrophages. Lentinan enhances cytotoxic activ-
ity and inflammatory cytokines of primary macrophages and 
RAW264.7 cell lines (13). It can also enhance the phenotypic 
and  functional  maturation  of  dendritic  cells  with  significant 
IL-12  production  (14).  Stimulatory  effects  of  lentinan  on  T 
cells  have  also  been  reported.  Lentinan  enhances  the  vi-
rus-specific T cell functions induced by DNA vaccine, acts as 
a vaccine adjuvant (15), and increases T cell functions in tu-
mor-bearing mice (16) and malaria-infected mice (10). In ad-
dition, lentinan is reported to enhance T cell functions in can-
cer patients (17). However, there is no report showing that 
lentinan directly activates T cells in vitro. It has been demon-
strated that lentinan indirectly activates T cells via IL-12 and 
IFN-γ produced by lentinan-activated macrophages and den-
dritic cells (18). However, lentinan might be an indirect acti-
vator of T cells and T cell activation might be observed only 
under in vivo conditions with mixed immune cell subsets. It 
has  been  reported  that  lentinan  increases  NK  cell-mediated 
killing of Yac-1 cells both in vitro and in vivo (19). However, 
this does not necessarily mean that lentinan directly activates 
NK  cells,  since  total  spleen  cells  were  used  in  this 
experiment. The only clear fact is that β-glucan directly acti-
vates  macrophages and dendritic cells, but the  effect of  β
-glucan on other immune cells remains controversial. Further 
in vitro studies with purified immune cell subsets are required 
t o  c l a r i f y  w h e t h e r  β- g l u c a n  d i r e c t l y  a c t i v a t e s  t h e s e  c e l l s .  
β-GLUCAN RECEPTORS 
Macrophages and dendritic cells have typical cell surface re-
ceptors called pattern recognition receptors (PRRs) that detect 
innately  non-self  molecules  including  pathogen-associated 
molecular  patterns  (PAMPs)  (20).  β-Glucans  might  act  as 
PAMPs and are recognized by PRRs, since β-glucans cannot 
directly penetrate cell membrane due to their large molecular 
size (3). The major PRRs for β-glucans might be dectin-1 and 
the  roll-like  receptor  (TLR).  Upon  binding  with  β-glucan, 
dectin-1 and TLR might inducing signaling cascade and acti-
vate immune cells. Other receptors, such as complement re-
ceptor 3 (CR3), scavenge receptors (SR), and lactosylceramide 
(LacCer),  might  be  involved  (20). 
DECTIN-1
Dectin-1 is a lectin that consists of four components: an ex-
tracellular carbohydrate-recognition domain, a short stalk re-
gion, a single transmembrane region, and a short 40 amino 
acid  intracellular  cytoplasmic  tail  (21).  Dectin-1  consists  of 
244 amino acids and has six cysteine residues. In particular, 
two amino acids (Trp221 and His223) located near the fourth 
cysteine residue appear to be critical for binding of β-glu-
cans (22). Dectin-1 specifically recognizes β-(1-3)(1-6) glu-
cans from fungi, plants, and bacteria (23). However, it is not 
reactive  toward  β-(1-4)  glucans  or  α-mannan  (24). 
    Binding of dectin-1 with β-glucans induces several signal-
ing pathways to activate innate immune responses, such as 
phagocytosis,  ROS  production,  and  inflammatory  cytokine 
production (25). The cytoplasmic tail of dectin-1 has an im-
munoreceptor  tyrosine-based  activation  (ITAM)-like  motif 
(YxxxI/Lx7YxxL)  to  activate  tyrosine  kinases  (26).  Upon  li-
gand  binding,  tyrosines  in  the  ITAM  sequences  are  phos-
phorylated by Src family kinases, providing a docking site for 
Syk (spleen tyrosine kinase) by interacting with the two SH2 
(Src homology 2) domains of Syk (26). The spacing between 
the  YxxxL  sequences  is  important  to  engage  both  SH2  do-
mains of Syk family kinase, thus contributing to enzyme acti-
vation (27). Activated phospholipase C γ (PLCγ) produces 
inositol  trisphosphate  and  diacylglycerol  (DAG)  (28).  Also, 
Syk activates the PI3K/Akt pathway, MAPK, NFAT, and NF-κB 
(29).Biological Activity of β-glucan
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TLRs
TLRs are expressed on macrophages, dendritic cells, B cells, 
T cells and endothelial cells and are type I transmembrane 
receptors of a novel protein family. At least 13 members of 
this family exist in human. TLRs can recognize diverse mi-
crobes including fungi, bacteria, viruses and protozoa. Several 
ligands  have  been  shown  to  bind  TLRs:  TLR2-zymosan, 
TLR3-dsRNA, TLR4-LPS, and TLR5-Flagellin, etc. (3). Binding 
of  specific  ligands  to  TLRs  induces  several  signaling  path-
ways,  such  as  My88-mediated  signaling  and  TRIF-mediated 
signaling. TLR signaling usually results in activation of NF-κB 
and MAPK signalings (30). There are many β-glucans that 
can bind to TLRs. For example, zymosan binds to TLR2/4 of 
macrophages and increases the cytokine production such as 
TNF-α and IL-12 via NF-κB signaling (31). β-Glucans iso-
lated from plants, such as Sparassis crispa, Phellinus linteus, 
Platycodon  grandiflorum,  Cordyceps  millitaris,  and  Angelica 
gigas Nakai, induce dendritic cell maturation through binding 
to TLR4 (32-37). Signalings downstream from TLRs or dectin-1 
might cross-talk with each other (38). Zymosan can bind both 
dectin-1 and TLR2, and both dectin-1/Syk and TLR/Myd88 sig-
nalings are required to fully induce the translocation of NF-κB 
subunits  to  the  nucleus  (39).
OTHER RECEPTORS
First identified over 25 years ago, CR3 can recognize carbohy-
drates (40). CR3 acts as an opsonic receptor for the comple-
ment component and as a nonopsonic receptor for a variety 
of exogenous ligands. CR3 is a heterodimeric transmembrane 
integrin  consisting  of  CD11b  (αm)  and  CD18  (β2)  chains. 
CD11b has two  binding  sites. One for  β-glucan is located 
within the C terminus, while the other for iC3b (cleaved com-
ponent 3 fragment of serum complement system) is located 
within the N-terminus (40). Binding of β-glucan to the C-ter-
minal lectin domain increases adhesion to microbial cells and 
activates  iC3b  pathways  causing  tumor  cytotoxicity  (41). 
Ligand binding of CR3 is known to mediate intracellular sig-
naling and induce a variety of cellular responses, including 
adhesion,  cytotoxicity,  phagocytosis  and  migration  (41). 
H o w e v e r ,  w h e t h e r  C R 3  d i r e c t l y  b i n d s  t o  β-glucan  is  still 
unclear. CR3-deficiency in NK cells reduced cytotoxicity, but 
CR3-deficient leukocytes are still capable of recognizing and 
responding to β-glucan (42). The β-glucan of small molec-
ular size binds to CR3 in NK cells and that of large molecular 
size binds dectin-1 and TLRs in macrophages and dendritic 
cells. 
    LacCer  (CDw17  and  Gal4Glc1Cer)  is  expressed  on  neu-
trophils and endothelial cells. LacCer recognizes a variety of 
microbes and pathogens, including fungi, such as Candida al-
bicans,  Cryptococcus  neoformans,  and  Saccharomyces  cer-
evisiae (43). It consists of a hydrophobic ceramide and a hy-
drophilic sugar moiety and is identified as a receptor for β
-glucan  (44).  The  interaction  of  β-glucan  with  LacCer  in-
duces  a  number  of  cellular  responses  in  vitro.  In  alveolar 
neutrophils, β-glucan from Pneumocystis carinii can induce 
the production of macrophage inflammatory protein-2 (MIP-2) 
and  TNF-α via  NF-κB  and  PKC  signaling.  Blocking  anti-
bodies to LacCer or CR3 are also reported to inhibit β-glucan 
binding  to  and  the  activation  of  human  neutrophils  (45). 
    SR are expressed on epithelial cells, endothelial cells and 
myeloid cells and comprise a family of proteins that are struc-
turally  diverse  and  have  a  range  of  cellular  functions  (46). 
SR were initially described in cultured macrophages in which 
they  mediate  cholesterol  uptake.  Based  on  their  structures, 
SR can be categorized into class A, B and C. SR-A has a colla-
gen-like domain, which is essential for ligand binding (47). 
SR recognizes a variety of ligands including LDL (low-density 
lipoprotein),  HDL  (high-density  lipoprotein),  selected  poly-
anionic molecules, and a number of microbes (47). SR has 
also been implicated in the recognition of β-glucan. Lentinan 
can bind to SR and activate multiple signals, such as PI3K, 
Akt  kinase,  and  MAPK  (47). 
SUMMARY
β-Glucans are potent immunomodulators that have multiple 
activities  such  as  anti-tumor  and  anti-infective  activities. 
However, how β-glucan exerts these diverse biological activ-
ities is still unknown. The first step mediating β-glucan ac-
tion might be immunostimulation. In particular, binding of β
- g l u c a n  t o  s p e c i f i c  r e c e p t o r s  i n  m a c r o p h a g e s  a n d  d e n d r i t i c  
cells  can  induce  the  production  of  various  cytokines,  in-
directly activating other immune cells such as T cells and B 
cells  under  in  vivo  conditions.  Systemic  immunostimulation 
might be the main route in preventing the growth of cancer 
cells  and  infective  microorganisms  in  the  host.  Several  β
-glucan receptors in macrophages and dendritic cells, such as 
dectin-1 and TLRs, might play a key role in the recognition 
of β-glucans, but the exact signaling pathways downstream 
from  the  respective  receptors  and  the  cross-talk  between Biological Activity of β-glucan
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them is unclear to date. If we can understand these issues 
in greater detail, β-glucans might be widely used in the ther-
apy  of  cancer  and  infectious  diseases.
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